PTEN-deficient GBM cells underwent treatment with olaparib (AZD-2281, Ku-0059436), a clinically-relevant PARPi regularly used in the treatment of BRCA-deficient breast, ovarian, and endometrial cancer [27]. Here, PTEN is linked to endometrial cancer.